Human health risk assessment for peroxisome proliferators: more than 30 years of research.
Substances like gemfibrozil, clofibrate and fenofibrate, widely used in human care for their hypolipidemic effects, belong to a larger class of chemicals called peroxisome proliferators (PPs). PPs, by binding and activing the peroxisome proliferator-activated receptor alpha (PPARalpha), modulate gene involved in lipid homeostasis both in human and in rodent. In a different way, long term administration of PPs results in hepatocarcinogenesis only in rodent. Although the phenomenon is known since more than 30 years, the exact mechanism is not well understood and the human health risks are not established. In this mini-review is inspected the major findings done in the different species and illustrates the possible doubts for human health by the use of PPs.
Fidaleo
Marco
M
Department of Cellular and Developmental Biology, University of Rome La Sapienza, Rome, Italy. marco.fidaleo@uniroma1.it
D000818:Animals; D006801:Humans; D008099:Liver / Q000187:drug effects*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced; D047493:PPAR alpha / Q000378:metabolism; D020025:Peroxisome Proliferators / Q000009:adverse effects*; D051381:Rats; D018570:Risk Assessment; D013045:Species Specificity
D047493:PPAR alpha; D020025:Peroxisome Proliferators